Although it is essential to validate these findings through in vivo studies to elucidate the translational potential of HDAC6 inhibition in clinical settings, our experimental results demonstrate the therapeutic promise of HDAC6 inhibitors as potent anticancer agents against RCC. The gene discussed is HDAC6; the disease is renal cell carcinoma.